Burning Rock Biotech Limited
As of Oct 22, 2026, Burning Rock Biotech is in Stage 1, the basing phase, now in week 8 (since Sep 1, 2026). It closed at $13.25, 67.7% below its 52-week high and below its 200-day average, which is falling.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BNR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BNR among Diagnostics & Research15th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …15 | BNR | Stage 1 · wk 8 | 77 | −12.1% |
Burning Rock Biotech: quick answers
What stage is Burning Rock Biotech in?
As of Oct 22, 2026, Burning Rock Biotech (BNR) is in Stage 1, the basing phase. It entered Stage 1 on Sep 1, 2026 and is in week 8. What the four stages mean
Is Burning Rock Biotech in an uptrend?
Not yet. Burning Rock Biotech is in Stage 1, a base that can come before an uptrend. It trades 20.9% below its 200-day average, which is falling.
How far is Burning Rock Biotech from its 52-week high?
Burning Rock Biotech closed at $13.25 on Oct 22, 2026, 67.7% below its 52-week high of $41.06. Its 52-week low is $7.04.
How has Burning Rock Biotech performed over the past year?
As of Oct 22, 2026, Burning Rock Biotech is up 30.5% over the past year and down 32.7% so far in 2026.
Which sector and industry is Burning Rock Biotech in?
Burning Rock Biotech is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.